Browse News

Found 54 articles

• Eikon Therapeutics Builds Leading Clinical Development Organization with Appointment of Senior Team with Extensive Industry Expertise

  6/1/2023

  Eikon Therapeutics, Inc. today announced its Clinical Development organization. Under the leadership of Roy Baynes, M.D., Ph.D., Chief Medical Officer of Eikon, this team of experienced industry professionals will be responsible for every stage of clinical development and accelerating the company’s lead pipeline candidates into and through trials and regulatory review.

• Ventyx Biosciences to Participate in Two Upcoming June 2023 Investor Conferences

  5/31/2023

  Ventyx Biosciences, Inc. announced that Company executives will participate in the following upcoming investor conferences.

• Ventyx Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress

  5/11/2023

  Ventyx Biosciences, Inc. announced financial results for the first quarter ended March 31, 2023, and highlighted recent pipeline and business progress.

• Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023

  5/4/2023

  Ventyx Biosciences, Inc. announced that it will report financial results for the first quarter ended March 31, 2023 after market close on May 11, 2023.

• Ventyx Biosciences to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

  3/24/2023

  Ventyx Biosciences, Inc. today announced that Company executives will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference being held on March 30, 2023.

• Ventyx Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Corporate Progress

  3/23/2023

  Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”) today announced financial results for the fourth quarter and full year ended December 31, 2022, and highlighted recent pipeline and business progress.

• Ventyx Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023

  3/15/2023

  Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”) today announced that it will report financial results for the fourth quarter and full year 2022 after market close on March 23, 2023.

• Ventyx Biosciences Provides Update on Silicon Valley Bank Financial Exposure

  3/11/2023

  Ventyx Biosciences, Inc., has learned that Silicon Valley Bank has been closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation as receiver.

• Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

  2/28/2023

  Ventyx Biosciences, Inc. today announced that Company executives will participate in the following upcoming investor conferences.

• Ventyx Biosciences Announces Pipeline Updates and Highlights Strategic Priorities at Investor R&D Day

  1/26/2023

  Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, is hosting an investor R&D Day today highlighting key aspects of Ventyx’s clinical-stage and discovery programs.

• Ventyx Biosciences Appoints Allison J. Hulme, Ph.D. and Onaiza Cadoret-Manier to its Board of Directors

  1/12/2023

  Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced the appointment of Allison J. Hulme, Ph.D. and Onaiza Cadoret-Manier to its board of directors.

• Ventyx Biosciences to Host R&D Event on January 26, 2023

  1/5/2023

  Ventyx Biosciences, Inc. announced that it will host an R&D event on Thursday, January 26, 2023 in New York City from 9-11:30 a.m. ET.

• Ventyx Biosciences Announces Dosing of the First Patient in the Phase 2 SERENITY Trial of VTX958 for the Treatment of Moderate to Severe Plaque Psoriasis

  12/1/2022

  Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that the first patient has been dosed in a Phase 2 trial of its selective, allosteric TYK2 inhibitor VTX958 for the treatment of moderate to severe plaque psoriasis.

• Ventyx Biosciences to Participate in Two Upcoming Investor Conferences - November 22, 2022

  11/22/2022

  Ventyx Biosciences, Inc. today announced that Company executives will provide a company overview during fireside chats at the following upcoming investor conferences.

• Ventyx Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress

  11/3/2022

  Ventyx Biosciences, Inc. announced financial results for the third quarter ended September 30, 2022 and highlighted recent pipeline and business progress.

• Ventyx Biosciences to Participate in Three Upcoming Investor Conferences in November 2022

  10/27/2022

  Ventyx Biosciences, Inc. announced that Company executives will provide a company overview during fireside chats at the following upcoming investor conferences:

• Ventyx Biosciences to Report Third Quarter 2022 Financial Results on November 3, 2022

  10/27/2022

  Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”) today announced that it will report financial results for the third quarter ended September 30, 2022 after market close on November 3, 2022.

• 

  Money on the Move: Marinus, Evotec, Ventyx and more (Updated)

  9/22/2022

  This week's money flowed into various therapeutic areas like cancer and inflammatory disorders, while government and philanthropic grants fund the fight against infectious diseases.

• Ventyx Biosciences Announces $176.6 Million Private Placement of Common Stock

  9/19/2022

  Ventyx Biosciences, Inc. announced today that it has entered into a stock purchase agreement for the sale of 5,350,000 shares of its common stock at an offering price of $33.00 per share.

• Alumis Appoints Jörn Drappa M.D., Ph.D., as Chief Medical Officer and Roman G. Rubio, M.D., as Senior Vice President, Clinical Development and Translational Medicine

  9/8/2022

  Alumis Inc., a precision immunology company that is reimagining the discovery, development and treatment of autoimmune disorders, announced that Jörn Drappa, M.D., Ph.D., has been appointed as chief medical officer.